J&J to seek appeal of $150M verdict in long-spanning HIV meds off-label marketing case

A whistleblower case dating back to 2012 culminated in a $150 million guilty verdict for Johnson & Johnson after a New Jersey jury determined that the company stepped on the federal False Claims Act as well as that of many states with misleading promotions of its HIV meds Prezista and Intelence.